1. Scrip
  2. >>Business

Ipsen CEO To Feed Group's Three Therapeutic Engines Fresh Assets In 2018

 
• By Sten Stovall

CEO David Meek Says Ipsen has more than $1bn for M&A use to expand its product line in oncology, neuroscience and rare diseases.

Fossil fuel
Ipsen's Disease Areas Are Oncology, Neuroscience and Rare Diseases • Source: Shutterstock

Ipsen's American CEO David Meek says he's adequately funded to transform the French pharmaceutical group through R&D and M&A, and make good on its aim to launch at least one new drug or new valuable indication every year going forward.

In an interview with Scrip, the former US army officer also rejected concerns over the pharma's cancer drug Cabometyx (cabozantinib)...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Ionis’s Dawnzera Becomes First RNA-Targeted HAE Prevention Drug

 
• By Joseph Haas

Dawnzera joins CSL’s recently approved Andembry as new additions to the crowded hereditary angioedema prevention market. It is priced at $57k per dose, but labeling includes four- or eight-week options.

Nicox Plots US Submission After Another Phase III Glaucoma Win

 
• By Kevin Grogan

The France-headquartered firm’s eye drop has demonstrated efficacy in a second pivotal trial.

Madrigal Regains Lead With Rezdiffra MASH Approval In EU

 
• By Joseph Haas

Four days after Wegovy became the second approved MASH therapy in the US, Rezdiffra gets the first European approval. Plans are for an initial launch in Germany.

Celldex Bullish On Barzolvolimab Despite Study Miss

 
• By Kevin Grogan

All eyes on chronic urticaria after eosinophilic esophagitis disappointment.

More from Business

Jazz Seeks Potential Expansion Of Epilepsy Franchise With Saniona Deal

 
• By Mandy Jackson

Deal Snapshot: Jazz, which sells Epidiolex for rare seizure disorders, will pay $42.5m up front to take over development of Saniona’s preclinical Kv7.2/Kv7.3 activator SAN2355 for epilepsy.

Madrigal Regains Lead With Rezdiffra MASH Approval In EU

 
• By Joseph Haas

Four days after Wegovy became the second approved MASH therapy in the US, Rezdiffra gets the first European approval. Plans are for an initial launch in Germany.

Celldex Bullish On Barzolvolimab Despite Study Miss

 
• By Kevin Grogan

All eyes on chronic urticaria after eosinophilic esophagitis disappointment.